Home

GV 2016 GP, L.P.

CIK 1722204 · last filed 2025-05-19

GV 2016 GP, L.P. is a corporate insider who has filed 4 SEC Form 4 insider transactions across 3 companies since 2017. Current disclosed insider exposure totals $81.7M across reported positions. The firm reports its address in Mountain View, CA. 16 SEC filings were submitted jointly with GV 2016 GP, L.L.C.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$81.73M

Companies

3

Total Filings

4

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
1600 AMPHITHEATRE PARKWAY
MOUNTAIN VIEW, CA 94043
Phone
(650) 335-5278
State of Incorporation
DE
Related Filers
GV 2016 GP, L.L.C. — 16 joint filings, latest 2025-05-19
Alphabet Inc. — 13 joint filings, latest 2025-05-19
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted 10%+ Owner 208,696 $11.19 $2.34M $0 1 2018-06-27
RCUS 10%+ Owner 3,125,312 $26.15 $81.73M $0 1 2018-03-19
X4 Pharmaceuticals, Inc (ASNS) Delisted 10%+ Owner 752 $0.08 $59 $0 1 2017-11-20

Recent Filings

4 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-05-19 — Other (J) +191,920,624 $0
2018-06-27 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Conv (C) +13,356,548 $0 EDGAR
2018-03-19 RCUS Conv (C) +12,501,248 $0 EDGAR
2017-11-20 X4 Pharmaceuticals, Inc (ASNS) Delisted Conv (C) +1,805,448 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.